Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

NCT01953926 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

582

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated to align with the sponsor's current development plans for neratinib. The decision was not based on any new efficacy or safety data for neratinib.

Conditions

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Interventions

DRUG: Neratinib
DRUG: Fulvestrant
DRUG: Trastuzumab
DRUG: Paclitaxel

Sponsor

Puma Biotechnology, Inc.